The Genital Herpes drugs in development market research report provides comprehensive information on the therapeutics under development for Genital Herpes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Genital Herpes. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Genital Herpes and features dormant and discontinued products.
GlobalData tracks 30 drugs in development for Genital Herpes by 23 companies/universities/institutes. The top development phase for Genital Herpes is preclinical with 18 drugs in that stage. The Genital Herpes pipeline has 29 drugs in development by companies and one by universities/ institutes. Some of the companies in the Genital Herpes pipeline products market are: Rational Vaccines, Assembly Biosciences and NanoViricides.
The key targets in the Genital Herpes pipeline products market include DNA Helicase, DNA Primase, and DNA.
The key mechanisms of action in the Genital Herpes pipeline product include DNA Helicase Inhibitor with three drugs in Phase III. The Genital Herpes pipeline products include eight routes of administration with the top ROA being Oral and 11 key molecule types in the Genital Herpes pipeline products market including Small Molecule, and Live Attenuated Vaccine.
Genital Herpes overview
Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite; fever; general sick feeling (malaise); muscle aches in the lower back, buttocks, thighs, or knees; and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications.
For a complete picture of Genital Herpes’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
